Menopausal genitourinary syndrome is a relatively new term introduced, being synonymous with vulvo-vaginal atrophy or atrophic vaginitis. This condition is chronic, progressive and characterizes the changes present in pre-menopause and menopause that lead to significant changes in the genital area and the lower urinary tract and negatively influence the quality of life and sex life. SGM is a condition characterized by genital symptoms (vaginal dryness, burning, itching, irritation, bleeding), sexual symptoms (pain during intercourse and other sexual dysfunction) and urinary symptoms (dysuria, frequency or urgency to urinate and recurrent urinary infections ). Several factors (such as age, sexual activity) can influence the clinical impact of these symptoms and the need to request a specialist consultation to receive treatment.
Vaginal dryness is the most common problem during menopause with important medical and psychological consequences. Unlike spontaneous hot flashes and night sweats, the symptoms of vaginal dryness that affect the lower urinary tract develop over time and are very annoying. The prevalence of vaginal dryness increases in the years following menopause and causes bothersome symptoms such as itching, burning and/or pain during sexual intercourse, which contributes to decreased libido.
The menopausal transition is an important moment in the aging of the genital tract. Cyclic, higher levels of estradiol in premenopausal change to varying levels in perimenopause and even lower levels in postmenopause. In cross-sectional studies, low estradiol levels are associated with a higher prevalence of vaginal dryness symptoms. However, the longitudinal relationships between the stages of menopausal transition, reproductive hormone changes, the development of vaginal dryness, and the potential sexual consequences of this symptom have not been well studied.
The prevalence of vaginal dryness increases in the years following menopause and causes disturbing symptoms such as itching, burning and/or pain during intercourse, which contributes to the decline of libido.
The menopausal transition is an important moment in the aging of the genital tract. Cyclic, higher levels of estradiol in premenopausal change to varying levels in perimenopause and even lower levels in postmenopause. In cross-sectional studies, low estradiol levels are associated with a higher prevalence of vaginal dryness symptoms. However, the longitudinal relationships between the stages of menopausal transition, reproductive hormone changes, the development of vaginal dryness, and the potential sexual consequences of this symptom have not been well studied.
The prevalence of vaginal dryness increases in the years following menopause and causes disturbing symptoms such as itching, burning and/or pain during intercourse, which contributes to the decline of libido.
≈17% among women
ged between 17 and 50 face this problem.
Vaginal dryness
Several studies show that vaginal dryness is considered a difficult topic to address.
Currently, estrogen therapy, approved for the treatment of vaginal atrophy, is often associated with adverse effects and multiple contraindications in menopausal patients. Among them, metabolic imbalances, mood changes, bloating, as well as the risk of developing ovarian cancer are the most common. Moreover, long-term use of estrogen therapy can lead to breast cancer and should therefore be limited.
Thus, there was a need to develop new alternative preparations that would provide therapeutic benefits and successfully replace estrogen therapy. One such strategy is the use of topical lubricants. But not all topical lubricants are the same.
Only 25% of women
will go to a doctor to treat this problem.
≈17% among women
aged between 17 and 50 face this problem.
Vaginal dryness
Several studies show that vaginal dryness is considered a difficult topic to address
Currently, estrogen therapy, approved for the treatment of vaginal atrophy, is often associated with adverse effects and multiple contraindications in menopausal patients. Among them, metabolic imbalances, mood changes, bloating, as well as the risk of developing ovarian cancer are the most common. Moreover, long-term use of estrogen therapy can lead to breast cancer and should therefore be limited.
Thus, there was a need to develop new alternative preparations that would provide therapeutic benefits and successfully replace estrogen therapy. One such strategy is the use of topical lubricants. But not all topical lubricants are the same.
Halova ovule swith hyaluronic acid is the excellent option for patients
who have contraindications to estrogen therapy or choose not to use estrogen.
An excellent option for patients who are contraindicated
to estrogen therapy or choose not to use estrogen.
